Back to School: How biopharma can reboot drug development. Access exclusive analysis here
An FDA advisory committee on Thursday voted 11-0 that Xolair omalizumab has a favorable risk benefit
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury